Click to cancel search
Login
Sign Up
Home Page
How It Works
Our Story
Symptom Checker
Second Opinion Finder
Newsroom
Partner With Us
MediFind Pro
FAQ
Are we missing a condition or feature you’d like to see? MediFind is always evolving and we’d love your feedback.
Submit Feedback
Advertising Policy
Privacy Policy
Terms & Conditions
Condition
Condition
Doctor
Symptom
Condition
Click to search for condition or expert
Login
Sign Up
Click to open main menu
Share
Share
Share
Click
Share
Share
Condition
Apolipoprotein C2 Deficiency
Symptoms, Doctors, Treatments, Research & More
Overview
Find a Doctor
Latest Research
Clinical Trials
Condition 101
What are the alternative names for Apolipoprotein C2 Deficiency?
Hyperlipoproteinemia, type Ib
APOC2 deficiency
Top Global Doctors
Click to see doctor options
RH
Elite
Robert A. Hegele
London, ON, CA
Click to see doctor options
DG
Elite
Daniel A. Gaudet
Chicoutimi, QC, CA
Click to see doctor options
PM
Elite
Philippe Moulin
Bron, 84, FR
Click to see doctor options
JW
Elite
Joseph L. Witztum
Endocrinology
Internal Medicine
San Diego, CA
Click to see doctor options
IG
Elite
Ira J. Goldberg
Endocrinology
Internal Medicine
New York, NY
Click to see doctor options
ZA
Elite
Zahid S. Ahmad
Endocrinology
Internal Medicine
Dallas, TX
Latest Research
Latest Advance
Study
Condition:
Familial Chylomicronemia Syndrome (FCS) or Hypertriglyceridemia
Journal:
Drug design, development and therapy
Treatment Used:
Volanesorsen
Number of Patients:
0
Published —
August 06, 2020
This article discusses volanesorsen in the treatment of familial chylomicronaemia syndrome (FCS), a rare disorder of lipid metabolism characterized by high levels of triglycerides (TGs).
Latest Advance
Study
Condition:
Familial Chylomicronemia Syndrome
Journal:
Journal of internal medicine
Treatment Used:
Lifelong Very Low-fat Diet
Number of Patients:
0
Published —
December 17, 2019
The study researched familial chylomicronemia syndrome.
Clinical Trials
Clinical Trial
Drug
Status:
Not yet recruiting
Study Type:
Drug
Participants:
60
Start Date:
October 1, 2020
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)
Clinical Trial
Drug
Status:
Recruiting
Study Type:
Drug
Participants:
16
Start Date:
December 9, 2019
Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency
